Pharmaceuticals, Biotechnology and Life Sciences
VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing…
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry EventsFREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) — Continuing…
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a…
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,…
LONDON, April 29, 2025 (GLOBE NEWSWIRE) — Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with…
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agentMELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE)…
– Oral and poster presentations will highlight advancements from ElevateBio’s two business units: Life Edit, its gene editing and R&D…
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the…
Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to…